Polaris Market Research today announced findings from its latest report, projecting the North America SGLT2 Inhibitors Market to grow from USD 7.32 billion in 2024 to USD 16.37 billion by 2034, at a CAGR of 8.4% during 2025–2034. The report profiles 10 leading companies across four segmentation categories: indication, drug, distribution channel, and country. Rising obesity, type 2 diabetes prevalence, and expanding cardiovascular and kidney indications are steadily expanding the regional market size.

Analyst Commentary on SGLT2 Inhibitor Industry Growth

“Rising obesity and type 2 diabetes prevalence, combined with expanding cardiovascular and kidney indications, are reshaping demand for SGLT2 inhibitors across the region, and that is powering market growth,” said an analyst at Polaris Market Research. “Manufacturers with differentiated combination therapies and broad pharmacy access are positioned to capture the next wave of patients.”

North America SGLT2 Inhibitors Market Statistics at a Glance

• 2024 Market Size: USD 7.32 billion
• 2025 Estimated Size: USD 7.93 billion
• 2034 Projected Size: USD 16.37 billion
• CAGR (2025–2034): 8.4%
• Largest Country (2024): United States
• Leading Drug (2024): Jardiance (Empagliflozin)

Key Growth Drivers, Top Companies and Segments Covered

Growth Drivers: Rising obesity rates, high-stress urban lifestyles, and continuing pharmaceutical innovation are the primary forces behind the market's expansion, alongside growing demand for effective glucose-lowering therapies. Trust for America's Health reports that the US adult obesity rate reached 41.9% between 2017 and 2020, raising the risk of type 2 diabetes. In January 2023, bexagliflozin was approved as an additional therapy for lowering blood glucose in patients with type 2 diabetes, according to the American Society of Nephrology, widening treatment options.

Major Companies Covered: AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., and Pfizer Inc., alongside Bristol-Myers Squibb Company, Sanofi, and Lexicon Pharmaceuticals, Inc. Participants focus on new formulations, combination therapies, local manufacturing, and educational outreach to physicians and patients.

Segments Covered: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, Others), By Drug (Farxiga, Inpefa, Invokana, Jardiance, Qtern), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Country (US, Canada).

👉 Download a Free Sample Report on Top Companies and Market Forecast 2034 →

https://www.polarismarketresearch.com/industry-analysis/north-america-sglt2-inhibitors-market 

Recent Developments in the SGLT2 Inhibitor Industry

• April 2024: Boehringer Ingelheim reported that its EMPACT-MI phase 3 trial showed a 10% reduction in the risk of heart failure hospitalization with Jardiance (empagliflozin).
• December 2023: Boehringer Ingelheim received European Commission approval for Jardiance in children aged ten and older with inadequately controlled type 2 diabetes.
• September 2023: Eli Lilly and Boehringer Ingelheim announced US FDA approval of Jardiance to reduce cardiovascular death and heart failure hospitalization risk in patients with chronic kidney disease.
• December 2022: Eli Lilly reported that a Phase III trial of Jardiance achieved a statistically significant blood glucose reduction in pediatric and adolescent patients with type 2 diabetes.

Industry Trends: Combination Therapies and Enhanced Formulations

Continual research is introducing advanced SGLT2 inhibitors, including combination therapies with other antidiabetic medications and enhanced formulations that broaden treatment choices. North America's advanced healthcare infrastructure supports rapid identification and management of diabetes, giving patients access to experienced practitioners and the latest therapies. Diets high in sodium, sugars, and unhealthy fats, together with low intake of fruits and vegetables, continue to feed hypertension, insulin resistance, and kidney damage, sustaining demand for treatment.

Segment Insights: Jardiance Leads Drugs, Type 2 Diabetes Anchors Demand

Jardiance (empagliflozin) accounted for the largest drug share in 2024 on the strength of clinical evidence showing reductions in cardiovascular mortality and heart failure hospitalization, and FDA approvals that extended its use to heart failure and chronic kidney disease beyond glycemic control. The drug segmentation also spans Farxiga, Inpefa, Invokana, and Qtern. By indication, type 2 diabetes remains central to demand because SGLT2 inhibitors control blood sugar while delivering cardiovascular protection, a valuable pairing for patients with common comorbidities.

Country Snapshot: US Leads, Canada Poised for Significant Growth

The US held the larger share of the regional market in 2024, supported by a substantial pharmaceutical research sector, prompt adoption of new SGLT2 inhibitors and combination therapies, and vigorous physician education. Canada is expected to see significant growth through 2034 as federal, provincial, and territorial authorities expand public health campaigns, screening initiatives, and diabetes self-management programs. In June 2020, Merck and Pfizer's STEGLATRO (ertugliflozin) met the primary endpoint in the VERTIS CV trial in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Why It Matters for Stakeholders Reviewing the Market Forecast 2034

For stakeholders researching top companies and the North America SGLT2 Inhibitors market forecast 2034, the underlying report benchmarks market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034. The analysis also applies Porter's Five Forces, PESTEL, and value chain frameworks, helping pharmaceutical companies, payers, and investors compare key players, track industry trends, and assess the pressure from alternative treatment options.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

battery-market

sports-nutrition-market

top-5-companies-driving-change-in-tampon-manufacturing

intelligent-building-automation-technologies-market

polycarbonate-sheet-market

unsaturated-polyester-resins-market

donkey-milk-market

ground-based-air-defense-systems-market

3d-printing-filaments-market